MMSI

The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories.

In a comparison of two Medical-Dental Supplies stocks, Henry Schein (HSIC) and Merit Medical (MMSI), both holding a Zacks Rank #2 (Buy), HSIC emerges as the superior value opportunity. HSIC has a lower forward P/E ratio of 15.72 compared to MMSI's 20.29, a better PEG ratio of 1.49 versus 1.94, and a lower P/B ratio of 2.46 versus 3.1. HSIC received a Value grade of A while MMSI received a C grade.

The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026.